Premium
ACALABRUTINIB PLUS PEMBROLIZUMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A PHASE 1/2 STUDY
Author(s) -
Witzig T.E.,
Maddocks K.,
Vos S.,
Lyons R.,
Edenfield W.,
Sharman J.,
Vose J.,
Yimer H.,
Wei H.,
Chan E.,
Patel P.,
Di Simone C.,
Gandhi M.,
Vaughn J.,
Kolibaba K.,
Cheson B.,
Samaniego F.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.139_2630
Subject(s) - medicine , gastroenterology , pembrolizumab , neutropenia , adverse effect , diffuse large b cell lymphoma , pneumonitis , chemoimmunotherapy , rituximab , progressive disease , oncology , surgery , lymphoma , cancer , chemotherapy , lung , immunotherapy